Treatment of growth hormone insensitivity syndrome (GHIS) with insulin-like growth factor (IGF-I).
The newly available IGF-I therapy in GHIS is effective in promoting growth and may eventually prevent dwarfism in these patients. Nevertheless, this therapy is still in its experimental phase. The effects of subcutaneous IGF-I injection on various metabolic components are complex due to the intricate effects and regulation of the components of the IGF system in general and in particular in GHIS. More experience with IGF-I treatment is needed to exploit the full potential of this new therapeutic agent.
Ranke
M B
MB
Section of Paediatric Endocrinology, Children's Hospital, University of Tübingen, Germany.
D000293:Adolescent; D000367:Age Factors; D001827:Body Height / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D006130:Growth Disorders / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011986:Receptors, Somatotropin / Q000172:deficiency* / Q000235:genetics; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D011986:Receptors, Somatotropin; D011994:Recombinant Proteins; D007334:Insulin-Like Growth Factor I